2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Practice Models, Quality Improvement, Quality of Care, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, MPN, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2443 Mismatched unrelated donors versus haploidentical donors in the era of post-transplant cyclophosphamide: A single-center retrospective study

Jonathan Bordat, MD, Eléonore Kaphan, MD2, Marie Robin, MD3, Alienor Xhaard, MD4, Flore Sicre-de-Fontbrune, MD5, Nathalie Dhedin, MD, PhD6, Florian Chevillon, MD7, Gerard Socie, MD, PhD8, Regis Peffault De Latour, MD, PhD9, David Michonneau, MD, PhD10
1 Saint-Louis Hospital, APHP, PARIS, France
2 Saint-Louis Hospital, APHP, PARIS, France
3 Saint-Louis Hospital, APHP, PARIS, France
4 Saint-Louis Hospital, APHP, PARIS, France
5 Saint-Louis Hospital, APHP, PARIS, France
6 Saint-Louis Hospital, APHP, PARIS, France
7 Saint-Louis Hospital, APHP, PARIS, France
8 Saint-Louis Hospital, APHP, PARIS, France
9 Saint-Louis Hospital, APHP, PARIS, France
10 Saint-Louis Hospital, APHP, PARIS, France

Introduction:

Initially developed for graft-versus-host disease (GVHD) prophylaxis for haploidentical (HAPLO) allogeneic hematopoietic stem cell transplantation (alloHSCT), post-transplant cyclophosphamide (PTCY) prophylaxis has recently been extended to mismatched unrelated donor (MMUD) transplants. Large registry studies comparing HAPLO and MMUD alloHSCT, both using PTCY-based GVHD prophylaxis, have yielded controversial results with some showing a trend toward better OS with lower non-relapse mortality (NRM) in the MMUD group. However, reliance on registry data introduces potential biases due to center-specific variations in clinical practice, complicating direct comparisons.

The aim of this single-center retrospective study was to compare outcomes after MMUD and HAPLO transplantation using PTCY-based GVHD prophylaxis for hematological malignancies.

 

Methods:

Patients aged ≥16 years with hematological malignancies who underwent a first alloHSCT from a MMUD (single allelic mismatch at one of the HLA-A, -B, -C, -DR, or -DQ loci) or a HAPLO donor, with PTCY-based GVHD prophylaxis, between January 2015 and February 2025 at Saint-Louis Hospital were included.

GVHD prophylaxis consisted of PTCY (50 mg/kg on days +3 and +4) combined with cyclosporine A and mycophenolate mofetil (30 mg/kg/day) starting at day +5.
 

Results:

A total of 219 patients were included: MMUD (n=56) and HAPLO (n=163). Median follow-up was 32.3 months (IQR, 25.0–40.3) and 45.0 months (IQR, 37.4–53.9), for MMUD and HAPLO, respectively. Due to earlier adoption of PTCY in HAPLO, the median transplant year was more recent for MMUD (2022.5 vs. 2021, p<0.01). MMUD recipients were older than HAPLO (median age 52.4 vs. 45.9 years, p=0.012), with a lower proportion of patients with an HCT-CI score of 0 (28.6% vs. 46.6%) and a higher proportion with high/very-high DRI (37.5% vs. 27.6%).

The primary indication for transplantation was acute leukemia in both groups (87.5% vs. 86.5%, p=0.79), predominantly AML (63.3% vs. 49.6%). Myeloablative conditioning (MAC) was used in 32.1% and 46.0% of MMUD and HAPLO patients, respectively (p=0.085) with thiotepa-busulfan-fludarabine being the most frequently used regimen for both MAC (88.9% vs. 68.0%) and RIC (89.5% vs. 81.8%). Based on our local practice, 73/75 MAC HAPLO patients received bone marrow grafts compared with only 3/18 MAC MMUD patients.

Graft failure occurred in 9/219 cases (4.2%), all in the HAPLO group (5.5%). Platelet recovery was faster in the MMUD group (mean: 24.8 vs. 29.5 days) whereas neutrophil recovery was similar (mean: 22.8 vs. 23.4 days), regardless of conditioning intensity.

At 2 years, overall survival (71.9% vs. 71.6%, HR 0.88 [95% CI 0.48–1.62], p=0.687), progression-free survival (66.9% vs. 64.2%, HR 0.93 [95% CI 0.54–1.61], p=0.802), cumulative incidence of relapse (20.1% vs. 21.0%, HR 0.8 [95% CI 0.41–1.56], p=0.516), and non-relapse mortality (13.1% vs. 14.8%, HR 1.11 [95% CI 0.46–2.69], p=0.818) were comparable between both groups. The MMUD group had a significantly higher D+100 incidence of grade II–IV acute GVHD (66.1% vs. 47.9%, HR 1.66 [95% CI 1.08–2.56], p=0.021), but rates of grade III–IV acute GVHD at D+100 (14.3% vs. 9.8%, HR 2.01 [95% CI 0.85–4.76], p=0.114) and 2-year chronic GVHD (34.8% vs. 35.0%, HR 0.87 [95% CI 0.51–1.50], p=0.600), including moderate/severe cases (29.3% vs. 28.9%, HR 0.88 [95% CI 0.49–1.58], p=0.657), were similar, resulting in comparable 2-year GVHD-free, relapse-free survival (35.9% vs. 37.2%, HR 1.03 [95% CI 0.70–1.53], p=0.874).

Infectious complications were similar, with low rates of EBV reactivation (5.3% vs. 9.2%, p=0.573), symptomatic BK virus (28.6% vs. 23.3%, p=0.294), and CMV infection in patients receiving letermovir prophylaxis (8.3% vs. 13.6%, p=0.546) in the MMUD and HAPLO groups, respectively. The incidence of non-infectious complications was also comparable between both groups, with notably similar cardiovascular events (13% vs. 11%, p=0.76). 

Conclusion:

This study demonstrates comparable efficacy and safety of PTCY-based MMUD and HAPLO transplantation, supporting greater flexibility in donor selection and broader access to alloHSCT. If confirmed, these findings could support prioritizing haploidentical donors when both options are available because of their logistical and economic advantages, including rapid donor availability and easier access to donor lymphocyte infusions.

Jonathan Bordat, MD: No relevant conflicts of interest to declare.